Journal article
Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study
The international journal of neuropsychopharmacology, v 4(2), pp 119-125
Jun 2001
PMID: 11466160
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The regional metabolic effects of fluoxetine were examined in patients with autism spectrum disorders. Six adult patients with DSM-IV and Autism Diagnostic Interview (ADI) diagnoses of autism (n = 5) and Asperger's syndrome (n = 1), entered a 16-wk placebo-controlled cross-over trial of fluoxetine. The patients received 18F-deoxyglucose positron emission tomography with co-registered magnetic resonance imaging at baseline and at the end of the period of fluoxetine administration. After treatment, the patients showed significant improvement on the scores of the Yale–Brown Obsessive–Compulsive Scale – Obsessions subscale and the Hamilton Anxiety Scale; Clinical Global Impressions – Autism scores showed 3 of the patients much improved and 3 unchanged. Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex. Patients with higher metabolic rates in the medial frontal region and anterior cingulate when unmedicated were more likely to respond favourably to fluoxetine. These results are consistent with those in depression indicating that higher cingulate gyrus metabolic rates at baseline predict SRI response.
Metrics
Details
- Title
- Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study
- Creators
- Monte S Buchsbaum - Neuroscience PET Laboratory, Mt. Sinai School of Medicine, New York, USAEric Hollander - Neuroscience PET Laboratory, Mt. Sinai School of Medicine, New York, USAM Mehmet Haznedar - Neuroscience PET Laboratory, Mt. Sinai School of Medicine, New York, USACheuk Tang - Neuroscience PET Laboratory, Mt. Sinai School of Medicine, New York, USAJacqueline Spiegel-Cohen - Neuroscience PET Laboratory, Mt. Sinai School of Medicine, New York, USATse-Chung Wei - Neuroscience PET Laboratory, Mt. Sinai School of Medicine, New York, USAAndrea Solimando - Neuroscience PET Laboratory, Mt. Sinai School of Medicine, New York, USABradley R Buchsbaum - Neuroscience PET Laboratory, Mt. Sinai School of Medicine, New York, USADiana Robins - Neuroscience PET Laboratory, Mt. Sinai School of Medicine, New York, USACarol Bienstock - Neuroscience PET Laboratory, Mt. Sinai School of Medicine, New York, USACharles Cartwright - Neuroscience PET Laboratory, Mt. Sinai School of Medicine, New York, USASerge Mosovich - Neuroscience PET Laboratory, Mt. Sinai School of Medicine, New York, USA
- Publication Details
- The international journal of neuropsychopharmacology, v 4(2), pp 119-125
- Publisher
- Cambridge University Press; Cambridge, UK
- Number of pages
- 7
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- A.J. Drexel Autism Institute
- Web of Science ID
- WOS:000169852900003
- Scopus ID
- 2-s2.0-0034955752
- Other Identifier
- 991014878035904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Clinical Neurology
- Neurosciences
- Pharmacology & Pharmacy
- Psychiatry